Skip to main content
. 2017 Jun 27;8(37):61674–61686. doi: 10.18632/oncotarget.18669

Figure 4. Overexpression of PTCH1 prevents the impact of silencing IGFBP-2 on EMT markers.

Figure 4

(A) Western blot and (B) qRT-PCR was performed to verify PTCH1 overexpression. (C) Western blot and (D) immunofluorescence staining analysis results showed that overexpression of PTCH1 prevents the impact of silencing IGFBP-2 on the expression of epithelial markers (E-cadherin) and the expression of mesenchymal markers (Vimentin and N-cadherin) (Original mignification, 20×). Data was reported as means ± SD for three independent experiments. ** compared with control, P<0.01.